Existing home sales climbed in November to a ten-year high but the markets opened flat with the Dow slipping 12 points to 19,961. Nasdaq lost 8 points to 5,474.
On the upside
TDK will pay a premium of approximately $1.3 billion in cash to acquire InvenSense (NYSE: INVN).
Calithera Biosciences (Nasdaq: CALA) will collaborate with Bristol-Myers Squibb (NYSE: BMY) to evaluate Bristol-Myers Squibb's Opdivo in combination with Calithera's CB-839 in patients with clear cell renal cell carcinoma.
Euroseas (Nasdaq: ESEA) will acquire an Ultramax drybulk carrier.
On the downside
xG Technology (Nasdaq: XGTI) priced its public offering with expected total gross proceeds of approximately $10 million.
The Finish Line (Nasdaq: FINL) widened third quarter losses more than expected and lowered its full year forecast.
Merrimack Pharmaceuticals (Nasdaq: MACK) halted a Phase 2 HERMIONE study of MM-302 in HER2-positive metastatic breast cancer patients.
In the broad market, advancing issues outpaced decliners by a margin of more than 10 to 9 on the NYSE while decliners edged out advancers by 7 to 5 on Nasdaq. The broader S&P 500 index slipped 2 points to 2,268. Bitcoin surged $34 to $823.
